These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35781058)

  • 1. Efficacy and safety of HER2-targeted inhibitors for metastatic colorectal cancer with HER2-amplified: A meta-analysis.
    Gao M; Jiang T; Li P; Zhang J; Xu K; Ren T
    Pharmacol Res; 2022 Aug; 182():106330. PubMed ID: 35781058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC).
    Chitkara A; Bakhtiar M; Sahin IH; Hsu D; Zhang J; Anamika F; Mahnoor M; Ahmed R; Gholami S; Saeed A
    Curr Oncol; 2023 Sep; 30(9):8266-8277. PubMed ID: 37754515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2-Positive Metastatic Colorectal Cancer.
    Robinson HR; Messersmith WA; Lentz RW
    Curr Treat Options Oncol; 2024 May; 25(5):585-604. PubMed ID: 38539034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment.
    Yang L; Li W; Lu Z; Lu M; Zhou J; Peng Z; Zhang X; Wang X; Shen L; Li J
    BMC Cancer; 2022 Apr; 22(1):355. PubMed ID: 35365123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of HER2-targeted therapy in patients with colorectal cancer: What should we expect from a meta-analysis?
    Wang M; Su J; Lu J; Yang Z; Wang J; Zhong Y; Zeng T; Shen K; Lin S
    Clin Res Hepatol Gastroenterol; 2023 Feb; 47(2):102078. PubMed ID: 36627051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis.
    Fan Q; Lv W; Xu Y; Dong Y; Xiang Z; Wang J
    Curr Pharm Des; 2020; 26(26):3171-3186. PubMed ID: 32067605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis.
    Li Z; Guo S; Xue H; Li L; Guo Y; Duan S; Zhu H
    Front Pharmacol; 2023; 14():1183514. PubMed ID: 37426807
    [No Abstract]   [Full Text] [Related]  

  • 8. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
    Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
    Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
    Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
    BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
    DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
    Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
    De Cuyper A; Van Den Eynde M; Machiels JP
    Clin Colorectal Cancer; 2020 Jun; 19(2):65-72. PubMed ID: 32229076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
    Siena S; Di Bartolomeo M; Raghav K; Masuishi T; Loupakis F; Kawakami H; Yamaguchi K; Nishina T; Fakih M; Elez E; Rodriguez J; Ciardiello F; Komatsu Y; Esaki T; Chung K; Wainberg Z; Sartore-Bianchi A; Saxena K; Yamamoto E; Bako E; Okuda Y; Shahidi J; Grothey A; Yoshino T;
    Lancet Oncol; 2021 Jun; 22(6):779-789. PubMed ID: 33961795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis.
    Zhang X; Yang Z; An Y; Liu Y; Wei Q; Xu F; Yao H; Zhang Z
    World J Surg Oncol; 2022 Mar; 20(1):93. PubMed ID: 35331250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
    Kawalec P; Łopuch S; Mikrut A
    Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.
    Lv ZC; Ning JY; Chen HB
    Tumour Biol; 2014 Dec; 35(12):11741-50. PubMed ID: 25417200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study.
    Strickler JH; Hsu LI; Wright P; Stecher M; Siadak MF; Palanca-Wessels MC; Yu J; Zhang N; Espenschied CR; Lang K; Bekaii-Saab TS
    J Natl Compr Canc Netw; 2023 Aug; 21(8):805-812.e1. PubMed ID: 37549907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.